|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
159,588 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$13,270,852 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
10 |
19 |
27 |
56 |
End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pyott David E I |
Director |
|
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
45,030 |
|
- |
|
Meier Richard A |
Director |
|
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
115,547 |
|
- |
|
Heron Elaine J |
Director |
|
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
92,121 |
|
- |
|
Dere Willard H |
Director |
|
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
27,580 |
|
- |
|
Alles Mark J |
Director |
|
2023-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,190 |
15,095 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2023-05-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
210 |
80,474 |
|
- |
|
Burkhart Erin |
GVP, Chief Accounting Officer |
|
2023-05-16 |
4 |
D |
$92.02 |
$73,248 |
D/D |
(796) |
14,094 |
|
- |
|
Heron Elaine J |
Director |
|
2023-05-12 |
4 |
D |
$93.93 |
$576,448 |
D/D |
(6,137) |
87,931 |
|
- |
|
Heron Elaine J |
Director |
|
2023-05-12 |
4 |
OE |
$67.81 |
$576,385 |
D/D |
8,500 |
94,068 |
|
- |
|
Meier Richard A |
Director |
|
2023-05-12 |
4 |
D |
$93.93 |
$576,448 |
D/D |
(6,137) |
111,357 |
|
- |
|
Meier Richard A |
Director |
|
2023-05-12 |
4 |
OE |
$67.81 |
$576,385 |
D/D |
8,500 |
117,494 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-12 |
4 |
D |
$93.93 |
$3,755,415 |
D/D |
(39,981) |
432,732 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-12 |
4 |
OE |
$67.81 |
$3,153,165 |
D/D |
46,500 |
472,713 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-11 |
4 |
AS |
$94.55 |
$2,840,226 |
D/D |
(30,000) |
426,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-11 |
4 |
OE |
$67.81 |
$2,034,300 |
D/D |
30,000 |
456,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-10 |
4 |
AS |
$94.65 |
$2,845,397 |
D/D |
(30,000) |
426,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-10 |
4 |
OE |
$67.81 |
$2,034,300 |
D/D |
30,000 |
456,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-09 |
4 |
AS |
$94.22 |
$2,847,973 |
D/D |
(30,000) |
426,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-05-09 |
4 |
OE |
$67.81 |
$2,034,300 |
D/D |
30,000 |
456,213 |
|
- |
|
Guyer Charles Greg |
EVP, Chief Technical Officer |
|
2023-05-04 |
4 |
D |
$95.45 |
$410,626 |
D/D |
(4,302) |
45,401 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2023-04-28 |
4 |
A |
$66.88 |
$21,200 |
D/D |
317 |
176,504 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2023-04-28 |
4 |
A |
$66.88 |
$21,267 |
D/D |
318 |
65,804 |
|
- |
|
Davis George Eric |
EVP, Chief Legal Officer |
|
2023-04-28 |
4 |
A |
$66.88 |
$21,201 |
D/D |
317 |
80,684 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2023-04-28 |
4 |
A |
$66.88 |
$21,201 |
D/D |
317 |
426,213 |
|
- |
|
Guyer Charles Greg |
EVP, Chief Technical Officer |
|
2023-04-28 |
4 |
A |
$66.88 |
$15,984 |
D/D |
239 |
49,703 |
|
- |
|
1285 Records found
|
|
Page 5 of 52 |
|
|